MG
MYGN icon

Michael Gelband’s Myriad Genetics MYGN Stock Holding History

Michael Gelband’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.21M Buy
+212,179
New +$963K 0.01% 1008
2026
Q1 		– Sell
-313,370
Closed -$1.93M – 1903
2025
Q4 		$1.93M Buy
313,370
+291,830
+1,355% +$2.12M 0.02% 781
2025
Q3 		$156K Sell
21,540
-40,144
-65% -$238K ﹤0.01% 1409
2025
Q2 		$328K Sell
61,684
-87,009
-59% -$514K ﹤0.01% 1230
2025
Q1 		$1.32M Buy
+148,693
New +$1.79M 0.01% 841
2024
Q3 		– Sell
-170,287
Closed -$4.17M – 1927
2024
Q2 		$4.17M Buy
170,287
+91,221
+115% +$2M 0.03% 471
2024
Q1 		$1.69M Buy
+79,066
New +$1.7M 0.01% 770
2023
Q4 		– Sell
-17,960
Closed -$288K – 1850
2023
Q3 		$288K Sell
17,960
-343,657
-95% -$6.54M ﹤0.01% 1429
2023
Q2 		$8.38M Buy
+361,617
New +$7.89M 0.07% 290
2023
Q1 		– Sell
-12,300
Closed -$178K – 2001
2022
Q4 		$178K Buy
+12,300
New +$229K ﹤0.01% 1474
2021
Q1 		– Sell
-23,437
Closed -$463K – 2429
2020
Q4 		$463K Buy
+23,437
New +$378K ﹤0.01% 1302
2020
Q3 		– Sell
-36,839
Closed -$418K – 2065
2020
Q2 		$418K Buy
+36,839
New +$523K 0.01% 1165

Other funds holding MYGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Michael Gelband's MYGN Position: Q2 2026 in Review

Michael Gelband opened a new position in Myriad Genetics (MYGN) in Q2 2026: 212,179 shares worth $1.21M. The stake represents 0.01% of the portfolio and ranks #1008 among its holdings. This is a return to the name: Michael Gelband previously reported a position in MYGN as recently as Q4 2025.

Michael Gelband first reported a position in MYGN in Q2 2020 and has held it in 12 quarters since. The position peaked at $8.38M in Q2 2023. 195 funds tracked by Wall St. Rank hold MYGN as of Q2 2026.

  • Michael Gelband held 212,179 shares of Myriad Genetics worth $1.21M as of Q2 2026.
  • Myriad Genetics was a new Michael Gelband position in Q2 2026.
  • Myriad Genetics made up 0.01% of Michael Gelband's portfolio in Q2 2026, its #1008 holding.
  • Michael Gelband first reported a position in Myriad Genetics in Q2 2020 and has held it in 12 quarters since.
  • Michael Gelband's Myriad Genetics position peaked at $8.38M in Q2 2023.
  • 195 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2026.

Based on ExodusPoint Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.